安帝君斯 AGEN 深 沪
等待开盘 05-18 09:30:00 美东时间
3.58
0.000
0.00%
华盛通- 最 高3.60
- 今 开3.52
- 成交量 51.04万股
- 最 低 3.42
- 昨 收 3.58
- 总市值 1.49亿
- 52周最高 7.34
- 市盈率 静 --
- 换手率 1.23%
- 52周最低 2.71
- 委 比 31.69%
- 总股本 4164.24万
- 历史最高 202.5868
- 量 比 0.57
- 振 幅 5.03%
- 历史最低 1.38
- 每 手 1
- 风险率 0.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Agenus Announces Resignation of Principal Accounting Officer
Agenus ( ($AGEN) ) has shared an update. On May 12, 2026, Agenus Inc. disclosed...
05-16 04:32
Agenus Announces Publication Of Phase 1b Data Evaluating Botensilimab In Combination With Balstilimab In Patients With Treatment-Refractory HCC
Published prospective cohort showed durable responses and manageable safety in patients with HCC following prior immunotherapyMedian overall survival of 12.3 months in a heavily pretreated population with poor prognostic
05-16 04:16
Agenus shares are trading lower. The company reported its Q1 financial results.
Agenus shares are trading lower. The company reported its Q1 financial results.
05-12 00:41
Agenus reports Q1 results
Agenus press release (AGEN): Q1 Cash and cash equivalents totaled $35.0 million as of March 31, 2026, compared with $3.0 million as of December 31, 2025. The company also expects to collect outstandi...
05-11 20:54
Immuno-oncology developer Agenus' Q1 revenue rises, posts profit
Immuno-oncology developer Agenus' Q1 revenue rises, posts profit Overview US immuno-oncology developer's Q1 revenue grew yr/yr, driven by BOT+BAL program Company reported positive net income for Q1, compared to loss in prior yr Agenus closed Zydus collaboration, strengthening capital and securing U.
05-11 20:53
Agenus Q1 FY26 net income swings to $39.2 million; revenue rises to $33.7 million
Agenus Q1 FY26 net income swings to $39.2 million; revenue rises to $33.7 million Agenus posted Q1 2026 revenue of USD 33.7 million, including USD 4.6 million in pre-commercial product revenue, while operating income swung to USD 15.1 million. Net income swung to USD 39.2 million, while cash and cas
05-11 20:45
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
Agenus Announces Phase II Data Showing Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab And agenT-797 in PD-1 Refractory Gastroesophageal Cancer; The Study Did Not Meet Its Primary Endpoint Of ORR
First study combining botensilimab (BOT) and balstilimab (BAL) with agenT-797 in gastroesophageal cancer shows disease control rate (DCR) of 77% in patients and long-term survival beyond 20 months in a subset of heavily
04-18 04:49
Agenus to present Phase II BOT+BAL plus agenT-797 data in PD-1 refractory GEC at AACR
Agenus to present Phase II BOT+BAL plus agenT-797 data in PD-1 refractory GEC at AACR Agenus flagged new Phase II trial data in PD-1 refractory gastroesophageal cancer for future presentation at AACR 2026. Study evaluates botensilimab with balstilimab alongside MiNK Therapeutics’ allogeneic iNKT cel
04-03 19:30
Agenus Securities Class Action Dismissed, Legal Risks Ease
Agenus ( ($AGEN) ) has issued an update. On March 24, 2026, the U.S. District C...
03-26 20:59
